The CCR5 axis is still INSANELY important for advanced COVID19, as well as (as always) HIV. Possibly Cancer. And likely dozens of other indications


Sorrento's antibody cocktail is showing In Vitro / "petri dish" results, which is great. It needs to be shown to work In Vivo / "living human." That's always much more difficult. It will take months to do that, and they will have to go through safety before efficacy.

It also needs to be caught early if one's hoping to avoid severe CV reactions...with the state of testing, I think it's reasonable to expect there will still be many people who have weak initial onset symptoms that have a severe immune response sneak up afterwards, and only then get treatment for the virus.The issue of lingering inflammatory agents still stands once it progresses.

I think Leronlimab will still have plenty of a role for CV, as it's likely to be the first with real data and real efficacy to hit the market, manufacturing capacity will be able to meet demand, Leronlimab handling and transportation and administration of a subcutaneous injection is vastly simpler than most treatments (stem cells, IV, RNA vaccines, etc)... I know they're now looking at IV administration for Leronlimab but that looks like it will have a corresponding and large benefit to efficacy as well. So... as far as the investing side of things, I'm looking at real revenue from CV but more importantly a fast track to approval... once it's approved for one indication, off-label use for HIV and some cancers and hopefully many other immune disorders will follow.